Development of a standardized definition for clinically significant bleeding in the ASPirin in Reducing Events in the Elderly (ASPREE) trial

Karen L Margolis, Suzanne E Mahady, Mark R Nelson, Diane G Ives, Suzanne Satterfield, Carlene Britt, Saifuddin Ekram, Jessica Lockery, Erin C Schwartz, Robyn L Woods, John J McNeil, Erica M Wood, Karen L Margolis, Suzanne E Mahady, Mark R Nelson, Diane G Ives, Suzanne Satterfield, Carlene Britt, Saifuddin Ekram, Jessica Lockery, Erin C Schwartz, Robyn L Woods, John J McNeil, Erica M Wood

Abstract

Background: Bleeding is the major risk of aspirin treatment, especially in the elderly. A consensus definition for clinically significant bleeding (CSB) in aspirin primary prevention trials is lacking in the literature.

Methods: This paper details the development, modification, application, and quality control of a definition for clinically significant bleeding in the ASPirin in Reducing Events in the Elderly (ASPREE) trial, a primary prevention trial of aspirin in 19,114 community-dwelling elderly men and women. In ASPREE a confirmed bleeding event needed to meet criteria both for substantiated bleeding and clinical significance. Substantiated bleeding was defined as: 1) observed bleeding, 2) a reasonable report of symptoms of bleeding, 3) medical, nursing or paramedical report, or 4) imaging evidence. Bleeding was defined as clinically significant if it: 1) required transfusion of red blood cells, 2) required admission to the hospital for >24 h, or prolonged a hospitalization, with bleeding as the principal reason, 3) required surgery to stop the bleeding, or 4) resulted in death. Bleeding sites were subclassified as upper gastrointestinal, lower gastrointestinal, intracranial (hemorrhagic stroke, subarachnoid hemorrhage, subdural hematoma, extradural hematoma, or other), or other sites. Potential events were retrieved from medical records, self-report or notification from treating doctors. Two reviewers adjudicated each event using electronic adjudication software, and discordant cases were reviewed by a third reviewer. Adjudication rules evolved to become more strictly defined as the trial progressed and decision rules were added to assist with frequent scenarios such as post-operative bleeding.

Conclusions: This paper provides a detailed methodologic description of the development of a standardized definition for clinically significant bleeding and provides a benchmark for development of a consensus definition for future aspirin primary prevention trials.

Trial registration: ASPREE is registered on the International Standard Randomized Controlled Trial Number Register (ISRCTN83772183) and on clinicaltrials.gov (NCT01038583).

Keywords: Aspirin; Bleeding; Hemorrhage; Methods; Primary prevention.

Figures

Fig. 1
Fig. 1
ASPREE Adjudication Process Chart.

References

    1. Antithrombotic Trialists Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86.
    1. Berger J.S., Brown D.L., Becker R.C. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. Am. J. Med. 2008;121(1):43–49.
    1. Guirguis-Blake J.M., Evans C.V., Senger C.A., O'Connor E.A., Whitlock E.P. Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force. Ann. Intern. Med. 2016;164(12):804–813.
    1. Chubak J., Whitlock E.P., Williams S.B., Kamineni A., Burda B.U., Buist D.S., Anderson M.L. Aspirin for the prevention of cancer incidence and mortality: systematic evidence reviews for the U.S. Preventive Services Task Force. Ann. Intern. Med. 2016;164(12):814–825.
    1. Whitlock E.P., Burda B.U., Williams S.B., Guirguis-Blake J.M., Evans C.V. Bleeding risks with aspirin use for primary prevention in adults: a systematic review for the U.S. Preventive Services Task Force. Ann. Intern. Med. 2016;164(12):826–835.
    1. Antithrombotic Trialists Collaboration, Baigent C., Blackwell L., Collins R., Emberson J., Godwin J., Peto R., Buring J., Hennekens C., Kearney P., Meade T., Patrono C., Roncaglioni M.C., Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849–1860.
    1. De Berardis G., Lucisano G., D'Ettorre A., Pellegrini F., Lepore V., Tognoni G., Nicolucci A. Association of aspirin use with major bleeding in patients with and without diabetes. JAMA. 2012;307(21):2286–2294.
    1. Li L., Geraghty O.C., Mehta Z., Rothwell P.M., Oxford Vascular S. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet. 2017;390(10093):490–499.
    1. Aspree Investigator Group Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial. Contemp. Clin. Trials. 2013;36(2):555–564.
    1. Mehran R., Rao S.V., Bhatt D.L., Gibson C.M., Caixeta A., Eikelboom J., Kaul S., Wiviott S.D., Menon V., Nikolsky E., Serebruany V., Valgimigli M., Vranckx P., Taggart D., Sabik J.F., Cutlip D.E., Krucoff M.W., Ohman E.M., Steg P.G., White H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123(23):2736–2747.
    1. McNeil J.J., Woods R.L., Nelson M.R., Murray A.M., Reid C.M., Kirpach B., Storey E., Shah R.C., Wolfe R.S., Tonkin A.M., Newman A.B., Williamson J.D., Lockery J.E., Margolis K.L., Ernst M.E., Abhayaratna W.P., Stocks N., Fitzgerald S.M., Trevaks R.E., Orchard S.G., Beilin L.J., Donnan G.A., Gibbs P., Johnston C.I., Grimm R.H., Aspree Investigator Group Baseline characteristics of participants in the ASPREE (ASPirin in reducing events in the elderly) study. J Gerontol A Biol Sci Med Sci. 2017
    1. Gibson C.M., Mehran R., Bode C., Halperin J., Verheugt F.W., Wildgoose P., Birmingham M., Ianus J., Burton P., van Eickels M., Korjian S., Daaboul Y., Lip G.Y., Cohen M., Husted S., Peterson E.D., Fox K.A. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N. Engl. J. Med. 2016;375(25):2423–2434.
    1. Schulman S., Kearon C., Subcommittee on control of anticoagulation of the Scientific Standardization, committee of the International Society on Thrombosis Haemostasis Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692–694.
    1. Peto R., Gray R., Collins R., Wheatley K., Hennekens C., Jamrozik K., Warlow C., Hafner B., Thompson E., Norton S. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988;296(6618):313–316.
    1. Steering Committee of the Physicians' Health Study Research Group Final report on the aspirin component of the ongoing Physicians' Health Study. N. Engl. J. Med. 1989;321(3):129–135.
    1. ETDRS Investigators Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. JAMA. 1992;268(10):1292–1300.
    1. Hansson L., Zanchetti A., Carruthers S.G., Dahlof B., Elmfeldt D., Julius S., Menard J., Rahn K.H., Wedel H., Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351(9118):1755–1762.
    1. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet. 1998;351(9098):233–241.
    1. De Gaetano G., Collaborative Group of the Primary Prevention Project Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet. 2001;357(9250):89–95.
    1. Ridker P.M., Cook N.R., Lee I.M., Gordon D., Gaziano J.M., Manson J.E., Hennekens C.H., Buring J.E. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N. Engl. J. Med. 2005;352(13):1293–1304.
    1. Ogawa H., Nakayama M., Morimoto T., Uemura S., Kanauchi M., Doi N., Jinnouchi H., Sugiyama S., Saito Y., Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes Trial I. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300(18):2134–2141.
    1. Belch J., MacCuish A., Campbell I., Cobbe S., Taylor R., Prescott R., Lee R., Bancroft J., MacEwan S., Shepherd J., Macfarlane P., Morris A., Jung R., Kelly C., Connacher A., Peden N., Jamieson A., Matthews D., Leese G., McKnight J., O'Brien I., Semple C., Petrie J., Gordon D., Pringle S., MacWalter R., Prevention of Progression of Arterial D., Diabetes Study G., Diabetes Registry G., Royal College of Physicians E. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840.
    1. Fowkes F.G., Price J.F., Stewart M.C., Butcher I., Leng G.C., Pell A.C., Sandercock P.A., Fox K.A., Lowe G.D., Murray G.D., Aspirin for Asymptomatic Atherosclerosis T. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010;303(9):841–848.
    1. Ikeda Y., Shimada K., Teramoto T., Uchiyama S., Yamazaki T., Oikawa S., Sugawara M., Ando K., Murata M., Yokoyama K., Ishizuka N. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA. 2014;312(23):2510–2520.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa